TY - JOUR
T1 - GINA 2020
T2 - Opportunities and challenges for primary care
AU - REG Adherence Working Group
AU - Kaplan, Alan
AU - van Boven, Job Fm
AU - Ryan, Dermot
AU - Tsiligianni, Ioanna
AU - Bosnic-Anticevich, Sinthia
N1 - Copyright © 2020.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - In 2019, it was reported that changes to asthma management reported in
the Global Initiative for Asthma “….might be considered the most fundamental
changes in asthma management in 30 years.”. These changes refer to the
recommendation that the treatment of asthma in adolescents and adults would no
longer include short acting ß2 agonist (SABA) only, but that people
with asthma should receive either symptom-driven inhaled corticosteroids
(ICS)-containing treatment (mild asthma) or daily ICS-containing treatment. The
fundamental reason for this shift was driven by concerns about the risks and
consequences associated with SABA only treatment, the need to improve the
day-to-day management of asthma symptoms to prevent exacerbations and emergent
evidence. These recommendations have subsequently been reinforced and
characterized in GINA 2020 and it is
reasonable to say that they are significant: not only in terms of an asthma
management framework, but also as a management approach in practice. This
opinion article specifically focuses on opportunities and challenges associated
with the implementation of GINA 2020 in primary care practice which need to be
recognised and addressed if the shift in asthma treatment paradigm is to be
successfully implemented into day-to-day practice.
AB - In 2019, it was reported that changes to asthma management reported in
the Global Initiative for Asthma “….might be considered the most fundamental
changes in asthma management in 30 years.”. These changes refer to the
recommendation that the treatment of asthma in adolescents and adults would no
longer include short acting ß2 agonist (SABA) only, but that people
with asthma should receive either symptom-driven inhaled corticosteroids
(ICS)-containing treatment (mild asthma) or daily ICS-containing treatment. The
fundamental reason for this shift was driven by concerns about the risks and
consequences associated with SABA only treatment, the need to improve the
day-to-day management of asthma symptoms to prevent exacerbations and emergent
evidence. These recommendations have subsequently been reinforced and
characterized in GINA 2020 and it is
reasonable to say that they are significant: not only in terms of an asthma
management framework, but also as a management approach in practice. This
opinion article specifically focuses on opportunities and challenges associated
with the implementation of GINA 2020 in primary care practice which need to be
recognised and addressed if the shift in asthma treatment paradigm is to be
successfully implemented into day-to-day practice.
U2 - 10.1016/j.jaip.2020.12.035
DO - 10.1016/j.jaip.2020.12.035
M3 - Article
C2 - 33373689
VL - 9
SP - 516
EP - 1519
JO - The Journal of Allergy and Clinical Immunology: In Practice
JF - The Journal of Allergy and Clinical Immunology: In Practice
SN - 2213-2198
IS - 4
ER -